Latest news with #Acinetobacterbaumannii
India Today
27-05-2025
- Health
- India Today
Antibiotic for deadly superbug behind hospital infections enters final trials
A new drug that could help combat one of the world's most dangerous drug-resistant bacteria is now entering its final stage of human trials. This potential breakthrough could help in the global fight against antibiotic pharmaceutical giant Roche announced on Monday that its experimental antibiotic, zosurabalpin, developed in collaboration with Harvard University, is moving into phase 3 final phase will test the drug on around 400 patients worldwide, focusing on its ability to treat infections caused by Acinetobacter baumannii, a bacteria known to cause severe hospital-acquired infections like pneumonia and Acinetobacter baumannii is a short, rod-shaped, gram-negative bacterium. Scientists call it an "opportunistic bacterial pathogen" as it affects people with weak immune systems, highly present in hospital baumannii has been recognised as an "urgent threat" by the US Centers for Disease Control and Prevention (CDC), and has become increasingly resistant to existing no new antibiotics targeting this superbug have been developed in over five decades. Swiss pharmaceutical giant Roche announced on Monday that its experimental antibiotic, zosurabalpin, developed in collaboration with Harvard University, is moving into phase 3 trials. () What sets zosurabalpin apart is that it works in a new way, using a mechanism that bacteria haven't yet found a way to resist. This fresh approach brings new optimism to a field where many treatments are failing due to antibiotic caused by drug-resistant bacteria are not only difficult to treat but also widespread. Globally, sepsis is estimated to cause 11 million deaths a year, while community-acquired pneumonia (CAP) kills 3 to 4 million people annually, especially among the elderly."Antimicrobial resistance is one of the biggest infectious disease challenges to public health. Our goal is to contribute new innovations to overcome this growing threat.',' said Michael Lobritz, Roche's global head of infectious diseases, told The Tsai, head of immunology and product development at Roche's US unit Genentech, added that Acinetobacter baumannii is present in every country. He added that the unique biology involved in developing zosurabalpin might even lead to future discoveries in the fight against other resistant phase 3 trial will compare the effects of zosurabalpin to current standard treatments, and if successful, the drug could be ready for approval by the end of this decade.
Irish Independent
27-05-2025
- Health
- Irish Independent
First new antibiotic in 50 years could help treat superbug labelled ‘urgent threat'
The drug, which targets one of the bacteria considered to pose the biggest threat to human health, has been hailed as an 'exciting' development in the fight against antibiotic resistance. Yesterday, Roche, the Swiss pharmaceutical giant, announced it will take zosurabalpin into the third and last phase of testing on humans. It is the first drug in five decades to show promise of tackling Acinetobacter baumannii, a pathogen which is described as a 'priority' by the World Health Organisation and an 'urgent threat' by the Centres for Disease Control and Prevention, the US national public health agency. The drug-resistant bacteria disproportionately impact patients who are in the hospital, causing infections such as pneumonia and sepsis. It is estimated that between 40pc and 60pc of infected patients, many of whom are immunocompromised because of conditions such as cancer, die as a result of the bug. One of the reasons it is so difficult to treat is that it has a double-walled 'membrane' protecting it from attack, so it is difficult to get drugs into it and to keep them in, experts said. Zosurabalpin, which has been developed alongside researchers at Harvard University, targets the 'machine' which stops the outer membrane from forming properly. It works differently to all existing antibiotics and it is hoped that it could lay the foundations for future drugs. 'Our goal is to contribute new innovations to overcome antimicrobial resistance, one of the biggest infectious disease challenges to public health,' Michael Lobritz, global head infectious diseases at Roche, said. The phase-three trial, which it is hoped will start later this year or in early 2026, will look at around 400 patients with a carbapenem-resistant Acinetobacter Baumannii (Crab) infection who will either receive zosurabalpin or the current standard of care. It is hoped that the drug will be approved by the end of the decade. Pharmaceutical companies have in the past been unwilling to pursue new antibiotics because of a difficult market in which the drugs are used sparingly to try and avoid resistance. However, the UN has warned that if nothing is done to address the issue, drug-resistant diseases could cause 10 million deaths each year by 2050.
Yahoo
26-05-2025
- Health
- Yahoo
First new antibiotic in 50 years to tackle superbug
The first new antibiotic in 50 years to tackle a common superbug will be tested on patients. The drug, which targets one of the bacteria considered to pose the biggest threat to human health, has been hailed as an 'exciting' development in the fight against antibiotic resistance. On Monday, Roche, the Swiss pharmaceutical giant, announced that it will take zosurabalpin into the third and last phase of testing on humans. It is the first drug in five decades to show promise of tackling Acinetobacter baumannii, a pathogen which is described as a 'priority' by the World Health Organisation and an 'urgent threat' by the Centers for Disease Control and Prevention, the US national public health agency. The drug-resistant bacteria disproportionately impact patients who are in the hospital, causing infections such as pneumonia and sepsis. It is estimated that between 40 and 60 per cent of infected patients, many of whom are immunocompromised because of conditions such as cancer, die as a result of the bug. One of the reasons it is so difficult to treat is that it has a double-walled 'membrane' protecting it from attack, so it is difficult to get drugs into it and to keep them in, experts say. Zosurabalpin, which has been developed alongside researchers at Harvard University, targets the 'machine' which stops the outer membrane from forming properly. It works differently to all existing antibiotics and it is hoped that it could lay the foundations for future drugs. Michael Lobritz, global head infectious diseases at Roche, said: 'Our goal is to contribute new innovations to overcome antimicrobial resistance, one of the biggest infectious disease challenges to public health.' The phase-three trial, which it is hoped will start later this year or in early 2026, will look at around 400 patients with a carbapenem-resistant Acinetobacter Baumannii (CRAB) infection who will either receive zosuarbalpin or the current standard of care. It is hoped that the drug will be approved by the end of the decade. Larry Tsai, senior vice president and global head of immunology and product development at Genentech, a unit of Roche, said that the drug-resistant bacteria 'are present in every country of the world' . He said that 'the innovative biology involved in this research could potentially reveal new insights into the structure of bacterial membranes, possibly leading to the discovery of new antibiotics in the future'. Pharmaceutical companies, including Roche, have in the past been unwilling to pursue new antibiotics because of a difficult market in which the drugs are used sparingly to try and avoid resistance. However, the UN has warned that if nothing is done to address the issue, drug-resistant diseases could cause 10 million deaths each year by 2050 and cause a worldwide financial crash. Dr Alistair Farley, scientific lead at the Ineos Oxford Institute, has welcomed zosurabalpin as an 'exciting development' for the field. 'There is an urgent unmet clinical need to develop new antibiotics against priority pathogens such as CRAB where antimicrobial resistance is a major concern,' he said. Dr Farley added that it 'may provide a route to the development of new drugs'. Studies showing that it worked 'extremely well' in test-tubes and mice were published in the journal Nature earlier this year. Prof Laura Piddock, scientific director of the Global Antibiotic Research and Development Partnership, said at the time that it provided 'definite hope' for other hard-to-treat infections. 'What is exciting about this discovery is that one of the building blocks that are part of the outer part of this bacterial cell is disrupted by this new drug,' Prof Piddock said. Antimicrobial resistance was declared by world leaders to be 'one of the most urgent global health threats' at the UN General Assembly earlier this year. The declaration committed members to establish independent panels on antimicrobial resistance, as many have done for climate change, and to reduce deaths linked to resistance by 10 per cent by 2030. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Indian Express
22-05-2025
- Health
- Indian Express
Can hospital superbugs chew up stents and implants? Here's what a new study says
A dangerous hospital-acquired bacteria can digest and live on plastics present in sutures, stents, wound dressings and implants in your body. Researchers from UK's Brunel University also found that when the bacteria used plastics as its food source, it led to the formation of more biofilms — barriers that can protect the pathogen from attacks by the immune system and antibiotics. The finding means that bacteria, such as the one they studied, could degrade medical implants, lead to infections at the site of the implant and cause infections that are harder to treat. What did the researchers find? There are bacteria in the environment that have developed the capacity to break down different types of plastics. So researchers wanted to see whether bacteria that cause infections in humans could also lead to such degradation within the body. For the study, scientists looked for different pathogens with genes that could potentially produce enzymes similar to the ones that environmental bacteria use to degrade plastics. While they found several hits, they selected a Pseudomonas aeruginosa sample that came from a patient's wound. They isolated an enzyme — which they named Pap1— that could digest a type of bio-degradable plastic frequently used in medical devices called polycaprolactone (PCL) plastic. The researchers found that the enzyme degraded 78 per cent of the plastic sample in just seven days. Importantly, the researchers found that the bacteria were not only degrading the plastic, they were also using it as their carbon source — effectively eating it. 'This means we need to reconsider how pathogens exist in the hospital environment. Plastics, including plastic surfaces, could potentially be food for these bacteria. Pathogens with this ability could survive for longer in hospitals,' Dr Ronan McCarthy, author and professor of biomedical sciences at Brunel University, said in a release. Why is this concerning? This is concerning for several reasons: One, bacteria could live on in hospitals or within a patient even when there aren't any other nutrients present. Two, they could degrade medical devices that use plastics, leading to their failure. This could lead to a rethink of materials that should be used for medical devices. Three, researchers found that the plastic-digesting bacteria could cause more severe infections. The researchers further found that the bacteria were using the broken down plastic molecules to create biofilms (a matrix made of sugars, proteins, fats and DNA) that make pathogens more resistant and difficult to treat. Four, degrading medical devices would also mean that the pathogens would be able to create pits and niches within the human body, where it could be shielded from the immune system and antibiotics, again causing difficult-to-treat infections. Are there other pathogens that could have this ability? Researchers found that other pathogens like Streptococcus pneumoniae, Klebsiella pneumoniae and Acinetobacter baumannii, too, carried genes that could potentially create plastic-digesting enzymes. More studies are needed. Importantly, the researchers found that Pap1 enzyme was structurally similar to known enzymes that can degrade even more hardy plastics such as PET bottles.
Yahoo
01-04-2025
- Business
- Yahoo
BioVersys secures patent claims in China for BV100
Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous formulation of rifabutin. The technology is being developed to combat resistant hospital infections caused by the Acinetobacter baumannii-calcoaceticus complex, including carbapenem-resistant strains (CRAB). BioVersys highlighted the urgent need for safe treatments for CRAB infections, which can have death rates in hospitals as high as 50%. According to recent epidemiology data, the company estimates that more than one million individuals in China suffer from severe CRAB-related pneumonia and bloodstream infections every year. BV100's mode of action enables rifabutin's 'active uptake' into the Gram-negative bacterial species Acinetobacter baumannii, targeting the ribonucleic acid (RNA)-polymerase enzyme. It is under development for treating ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP), and bloodstream infections (BSI). BioVersys CEO Dr Marc Gitzinger said: 'With the addition of China, we now have patents protecting BV100 granted in all the major markets, covering more than 25 countries. In our commitment to bring BV100 as a life-saving medicine to patients as fast as possible, this addition to our patent coverage is key due to the absolute number of patients affected by Acinetobacter infections in China. 'We are preparing to start a Phase I clinical trial in China soon, which will enable us to include China in our BV100 Phase III registration trial, which is planned to start in H2 2025.' In May 2019, the US Food and Drug Administration (FDA) granted the candidate qualified infectious disease product (QIDP) designation for VABP, BSI, and HABP, which paved the way for fast-track designation, priority review, and a five-year market exclusivity extension on approval of the initial QIDP indication. Last May, BioVersys and GSK announced the expansion of their strategic collaboration to expedite the clinical development of alpibectir (BVL-GSK098) for tuberculosis treatment. "BioVersys secures patent claims in China for BV100" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
